Document 6R2RGw8ZkEXJ4G32DKGe5r0em

DownloadRandom document
CORNINGHazleton MUTAGENICITY TEST ON T-6564 IN AN IN VIVO MOUSE MICRONUCLEUS ASSAY FRNAL REPORT Eli/, NOV r-, 1996 ,x 3,.4 0 ico@-L' AUTHOR Hemalatha Murli,Ph.D. PERFORMRNG LABORATORY Coming HazletonInc.(CHV) 9200 Leesburg Pike Vienna,Virginia22182 LABORATORY PROJECT IDENTIFICATION CHV StudyNo.: 17750-0455 SUBMITTED TO 3M Corporation Building220-2E-02,3M Center St.Paul,Minnesota 55144-1000 STUDY COMPLETION DATE November 1,1996 CHV StudyNo.: 17750-0455 1 of 26 CORNINGHazieton QUALITY ASSURANCE STATEMENT ProjecTtitleI:nVivoMouse MicronucleuAsssay ProjectNo.:20996 Assay No.: 17750 ProtocolNo.: 455 EditionNo.: 17,Modified for3M Corporation QualityAssurance inspectionsof thestudyand review of thefinalreportof theabove referenced projectwere conducted accordingtotheStandardOperatingProceduresofthe QualityAssurance Unit and accordingtothegeneralrequirementsof theappropriateGood LaboratoryPractice regulationsF.indingsfrom theinspectionasnd fmal reportreviewwere reportedtomanagement and tothestudydirectoron thefollowingdates: Insl2ection/Date FindingsR=orted Auditor Dosing/07/30/1996 07/30/1996 C. Orantes Harvest/08/l/1996 08/l/1996 C. Smith DraftReport Review/09/17,18/1996 09/18/1996 C. Orantes/C.Smith FinalReport Review/ 11/01 1996 11/01/1996 C. Smith (@dalitAyssurance Unit Date Released CHV StudyNo.: 17750-0455 2 CORNINGHazleton STUDY CONTLLANCEAND CERUFICATION The describedstudywas conductedincompliancewiththeGood LaboratoryPracticreegulations assetforthintheFood and Drup-Administratio(nFDA) Title21 oftheU.S.Code ofFederal RegulationPsart58,issuedDecember 22,1978,(effectiJvuene20, 1979)withany applicable amendments. Therewere no significadnetviationfsromtheaforementionerdegulationosrthe signedprotocotlhatwould affectheintegritoyfthestudyortheinterpretatioofnthetestresults. raw datahave beenreviewedby theStudyDirectorw,ho certifietshattheevaluatioonf the testarticlaespresentedhereinrepresentasn appropriatceonclusionwithinthecontextofthe studydesignand evaluatiocnriteria. Alltestand controrlesultisnthisreportaresupportedby an experimentaldatarecordand this recordhasbeenreviewedby theStudyDirector.Allraw data,documentationr,ecordsp,rotocol and a copy ofthefinalreportgeneratedas a resultofthisstudywillbe archivedinthestorage facilitioefsComing HazletonInc.foratleasotne yearfollowingsubmissionofthefinalreporto theSponsor.Aftertheone yearperiod,theSponsormay electtohave theaforementioned materialrsetaineidnthestoragefacilitioefsComing HazletonInc.foran additionapleriodof time,orsenttoa storagefacilitdyesignatebdy theSponsor. SubmittedBy: StudyDirector: HemalathaMurli,Ph.D. MannnalianCytogenetics DepartmentofGeneticand CellulaTroxicology Stud@ CompletionDate CHV StudyNo.: 17750-0-455 3 CORNINGHazleton TABLE OF CONTENTS Page No. SUMMARY ..............................................6............. 1.0 SPONSOR ...........................................7 ............ 2.0 MATERIAL (TestArticle.) .................................7 ............ 2.1 Client'Isdentification 2.2 Date Received 2.3 PhysicaDlescription 2.4 GeneticsAssay No. 3.0 TYPE OF ASSAY ......................................7............. 4.0 PROTOCOL NO ........................................7............ 5.0 STUDY DATES .......................................7............. 5.1 InitiationDate 5.2 ExperimentalStartDate 5.3 ExperimentalTerminationDate 6.0 SUPERVISORY PERSONNEL ...............................7............. 6.1 StudyDirector 6.2 LaboratorySupervisor 7.0 OBJECTIVE .........................................7............. 8.0 MATERIALS .........................................8............. 9.0 SOLUBILITY AND STABILITY ..............................8............. 10.0 DOSE SELECTION STUDY I ...............................9............. 10.1 Dose Selection 10.2 DosingInformation 10.3 Resultsand Interpretation 10.4 Conclusion CHV StudyNo.: 17750-0-455 4 CORNINGHazieton 11.0 DOSE SELECTION STUDY Il ..............................1.1............ 11.1 Dose Selection 11.2 DosingInformation 11.3 Resultsand Interpretation 11.4 Conclusion 12.0 MICRONUCLEUS STUDY .................................1,............. 12.1 Dose Selection 12.2 MicronucleusAssay DosingInformation 13.0 BONE MARROW HARVEST, SLIDE PREPARATION AND ANALYSIS ......1.4. 14.0 EVALUATION CRITERIA .................................1.5............ 14.1 General 14.2 Data Presentatioand Interpretation 15.0 RESULTS AND INTERPRETATION ...........................16........... 16.0 CONCLUSION .......................................1.6............. 17.0 REFERENCES .......................................1.7............. 18.0 DEVIATION FROM THE SIGNED PROTOCOL .....................17........ 19.0 EXPERIMENT DATA TABLES ..............................18............ CHV StudyNo.: 17750-0455 5 CORNINGHazleton SUMMARY MutageriiTceistotynT-656i4nanInVivMoouseMicronuclAesussay Theobjectivoefthisinvivoassaywas toevaluatteheabilitoyfthetestarticlTe-,6564,toinduce micronucleiinbone marrow polychromaticerythrocyteosfCrl:CD-le(ICR) BR mice. Inthedose selectionstudy,thetestarticlweas solubilizeidndeionizedwater and dosed by oral gavage at1000, 1510,2010, 2540 and 3010 mg/kg ina firstriaalnd thendosed at1010, 1520, 2020, and 2530 mg/kg ina second vial.Sixanimals (threemales and threefemales)were assignedtoeach dose group. Animals were observedforfourdays afterdosing fortoxicsigns and/ormortality. Based on the resultsof the dose selectionstudy,the maximum toleratedose was estimatedas about 2000 mg/kg. Inthe micronucleusassay,thetestarticlweas solubilizeidndeionizedwater and dosed by oralgavage at498,995, and 1990 mg/kg. Ten animals(fivemales and five females)were randomly assignedtoeach dose/harvestimegroup. Vehicleand positivecontrol groups,euthanizedapproximately24 hours afterdosing,were includedintheassay.The animals dosed with thetestarticlweere euthanizedapproximately24,48 and 72 hours afterdosing for extractioonf thebone n=ow. Tle testmaterial,T-6564, didnot inducea significanitncreaseinmicronucleiinbone marro@Apolychromaticerythrocytesunder theconditionsof thisassayand isconsiderednegativeinthe mouse bone marrow micronucleustest. CHV StudyNo.: 17750-0455 6 CORNINGHazleton MutagenicTietsytonT-656i4nanInVivMoouseMicronuciAesussay 1.0 SPONSOR: 3M Corporation 2.0 MATERIAL (TestArticle) 2.1 Client'IsdentificatiTo-n6:564L-13167FC1015-X 2.2 DateReceived:May 30,1996 2.3 PhysicalDescriptionC:learcolorleslsiquid 2.4 GeneticsAssay No.: 17750 3.0 TYPE OF ASSAY: In Vivo Mouse MicronucleusAssay 4.0 PROTOCOL NO.: 455,Edition17,Modifiedfor'3MCorporation 5.0 STUDY DATES 5.1 InitiatiDoante: June4,1996 5.2 ExperimentalStartDate: July11,1996 5.3 ExperimentalTerminationDate: August22,1996 6.0 SUPERVISORY PERSONNEL 6.1 StudyDirector:HemalathaMurli,Ph.D. 6.2 LaboratorySupervisor:Monica Vegarra,B.S. 7.0 OBJECTIVE The objectivoefthisinvivoassaywas toevaluatteheabilitoyfthetestarticlTe-,6564,to inducemicronucleiinbone marrow polychromatiecrythrocyteosfCrl:CD-IT(ICR)BR mice. Thisstudywas conductedusingmodificationosftheproceduressuggestedby Heddleetal.(1983). CHV StudyNo.: 17750-0455 7 CORNINGHazleton 8.0 MATERIALS Adultmale and femalemice,straiCnrl:CD-1*(ICR)BP, were purchasedfrom Charles RiverLaboratoriePso,rtageN,fl.Thishealthyr,andom bredstraiwnas selectetdo maximize geneticheterogeneitaynd atthesame tiznaessureaccesstoa common source. The protocolforthisstudywas approvedt)@tvheCHV-IACUC priortotheinitiatioofn dosing. Animalswere housedfivepercaizeduringquarantinea,nd housed fiveperca2eat randomizationT.he temperaturaend relativheumidityweremaintainedat72:k6 'F and 55 15%, respectiveleyx,cepton July31, 1996,forthedefinitivsetudy,when the humiditywas recordedas75.1%. A 12-hourlight/2l-hourdarkcyclewas maintained.A cor=ercialdiet(PurinatCertifieLdaboratorPyelletst4 5002)andwaterwere available ad libitumforthedurationofthestudy.The feedwas analyzedby themanufacturerfor concentrationosf specifiehdeavy metals,aflatoxicnh,lorinatehdydrocarbons, organophosphatesa,nd specifiendutrientsT.he waterwas analyzedon a retrospective basisforspecifiemdicroor9anisms,pesticideasl,kalinithye,avy metals,and halogens. Sanitizecdagingwas usedforhousinetheanimals.Personnelhandlin2animalsor workingwithintheanimalfacilitiweesrerequiredtowear suitablperotectivgearments and equipment. Animalswere quarantinefdorsevendaysbeforebeingplacedon study.Animalswere randomlyassignedtostudygroupsand were individualwleyighedpriortodosing.All animalswere dosedbasedupon theindividuablody weights.Animals wereuniquely identifiebdy eartag.Dose ortreatmentgroupswereidentifiebdy cagecard/label. At theterminatioonfthestudya survivinagnimalswere euthanizedby COI-/02 inhalatiofno,llowedby C02 inhalatioannd penetratioonfthethorax.Any extraanimals notusedforthestudywere savedfortraining. 9.0 SOLUBILITY AND STABILITY The testarticlTe-,6564,was suppliedasa clearcolorleslsiquid.The specifigcravityof thetestarticlweas calculateidnthetestinlgaboratorays 1.22g/ml.Thisspecifigcra-,-ity was usedtopreparedosingstocksfortheassay. Deionizedwaterwas usedas thevehicle inthisassay.The detenninatioonfthetestarticlsetabiliutnyderthedosingconditionosf thisassayand thetestarticlceharacteristaiscdsefinedintheGLP regulationosfFDA (21 CFR 58.105)E,PA-TSCA (40CFR 792.105)a,nd EPA-FIFRA (40CFR 160.105)isthe responsibiliotfythesponsor. CHV StudyNo.: 17750-0-455 8 CORNINGHazleton 10.0 DOSE SELECTION STUDY I 10.1 Dose Selection Dose levelsof 1000,1510,2010,2540 and 3010 mg/kg were administeredby oral gavage forthefirsdtose selectiosntudy. 10.2 Dosing Information The animalsused inthefirsdtoseselectioanssaywere dosed on July11,1996. The weightrangeof theanimalsused inthedose rangefindingassaywas 30.9-35.1and 22.2-27.6grams,forthe males and females,respectivelyD.osills! solutionwsere preparedjustpriortodosingand were preparedby makiniza 301 mg/mi stockforthehighdose(3010 mg/kg ).Thiswas preparedby addiniz deioriizewdater(CHV, Lot # 19)up toa volume of 15.0ml to3.7mi of T-656.,4. resultinigna clearcolorlesssolution.Dilutionsof thisstockwere preparedfor the2540,2010, 1510 and 1000 mg/kg doselevels. Dosing was achievedusinga 10 ml/kg dosingvolume. Allanimalswere eight weeks and threedays oldatthetime ofdosing.An outlineof thedosingscheme isfound inthefollowingtable. Dosing Scheme forDose SelectionAssay I Treatment T-6564 1000 mg/kg 15 10 mg/kg 2010 mg/kg 2540 mg/kg 3010 m2Ag Male Female 3 3 3 3 3 3 3 3 A totalof '30ariimalswas used inthisassay.Alldosesgivenwere on an acute (one-timeonly)basis. 10.3 Resultsand Interpretation All animalswere examined afterdosingand dailythroughoutthedurationof the study(fourdays)fortoxiceffectasnd/ormortalitiesT.he anirnalobservationfsor thisassayaresummarized inthefollowingtable: CHV StudyNo.: 17750-0-455 9 CORNINGHazleton AnimalObservationfsorToxicitfyorDoseRangefindinAgssayI Time After Dose Dosing Level (hours) (mg/kg) Observations =0.2 all Normal 1000 Normal Male # 9761 and Female #s 9776 & 9788 found dead. 1510 Remaining males appeared hunched and hypoactive. 16.8 Remaining female appeared normal.* 2010, 2540, 3010 Normal =40.2 1000, 1510, 2010, 2540 Normal Male #s 9765 & 9767 found dead. 3010 Remaining male and allfemalesappearnormal. 1000 Normal 1510 =67.0 - 2010, 2540, 3010 1000 Male # 9766 found dead. Remaining male and female appeared normal. Normal Normal -88.5 1510 2010, 2540 Remaining niale# 9774 found dead. Remaining female appeared normal. Normal Remaining male # 9764 appearedhypoactiveand hunched 3010 with a rough haircoat.All femalesappeared normal. The mortalitydata forthisassay aresummarized in the follo%%intgable: CHV Study No.: 17750-0-455 10 CORNINGHazleton Summar-yofMortalitifeosrDoseRangefmdingI Treatment T-6564 1000 mg/kg 15 10 mg/kg 2010 mg/kg 2540 mg/kg 3010 mg/kg Male 0/3 3/3 0/3 0/3 2/@3 Female 0/3 2/') 0/3 0/3 10.4 Conclusion Based on theseresultst,he maximum tolerateddose could not be determined. 11.0 DOSE SELECTION STUDY E 11.1 Dose Selection Dose levelsof 1010,1520,2020 and 2530 mg/kg were administeredby oral gavage forthe second dose selectionstudy. 11.2 Dosing Information The animalsused inthe second dose selectionassay were dosed on July 24, 1996. The weight range of the animals used in the second dose range findingassav%%-as 30.1-35.8and 2').6-28.4grams, forthe males and females,Tespecti-,-elDyo.singsolutionswere preparedjustpriortodosingand were preparedby makin2 a 253 mg/mi stockforthehigh dose (25-'1m0g/kg ). This was preparedby addine deionizedwater (CHV, Lot # 20) up toa volwne of 14.0n-dto2.9 mJ of T-6564, resultinigna clearcolorlessolution.Dilutionsofthisstockwere preparedfor the 2020, 1520 and 10 10 mg/kg dose levels. Dosing was achievedusinga 10 ml/kg dosing volume. All animalswere eight weeks and two days oldatthetime ofdosing. An outlineof thedosing scheme is found inthe followingtable: CHV Study No.: 17750-0-455 11 CORNING Hazleton DosingScheme forDose SelectioAnssay II Treatment T-6564 1010 mg/kg 1520 mg/kg 2020 mg/kg 2530 mg/kg Male Female 3 3 3 3 3 3 3 3 A totalof24 animalswas usedinthisassay.Alldosesgivenwere on an acute (one-timoenly)basis. 11.3 Resultsand Interpretation Allanimalswereexamined afterdosingand dailythroughoutthedurationofthe study(thredeays)fortoxiceffectasnd/ormortalitieTsh.e animalobservations forthisassayaresummarized inthe followingtable: Animal ObservationsforToxicityforDose RangefindingAssay 11 Time After Dose Dosing Level Observations (hours) (mg/kg) =O.i,i.i All Normal & 15.6 =17.9 1520 Female # 1417 found dead. =21.6 1520 Male # 1405 founddead. Z39.5 All Normal =66.6 All Normal =90.4 All Normal T*hemortalitdyataforthisassavaresummarized inthefollowingtable: CHV StudyNo.: 17750-0-455 12 CORNINGHazleton SummaryofMortaUtifeosrDoseR2ngefindiInIg Treatment T-6564 1010 mg/kg 1520 mg/kg 2020 mg/k-g 2530 me,/kg Male 0/3 1/-,) 0/1@ 0/3 Female 0/3 1/3 0/3 0/1) 11.4 Conclusion Based on theseresultst,hemaximum tolerateddosewas estimatedas about 2000 mg/kg. 12.0 MICRONUCLEUS STUDY 12.1 Dose Selection Basedon resultfsrom thedoseselectiosntudy,doselevelsof 498,995,and 1990 mg/kg were testedinthisstudy. 12.2 MicronucleusAssay DosingInformation The animalsusedinthemicronucleusassaywere dosed on July30, 1996. Cyclophosphamide(CP),(CAS f,6055-19-2;Sigma,Lot 4 26HO473),theI>Ositive controlw,as solubilizeidnsterildeeionizedwater(Lot-419,preparedatCHV) and was administerebdy oralgavageat80.0mg/kg. The vehiclecontrol. deionizedwater(CHV, Lot 1'2r0),was administerecdoncbnently,%itthhetest articlaeta volumeof 10mukg. The weightrangeoftheanimalsusedinthe micronucleusassaywas 31.0-37.7and 22.4-28.3grams forthemales and females, respectivelTyh.e dosingsolutionfsortheassaywere preparedby makine a 199 mg/ml stockforthehighdose(1990mg/kg ).Thiswas preparedby adding deionizewdater(CHV, Lot'm20) up toa volume of30.0ml to4.9ml ofT-6564, resultinigna clearcolorlesssolutionD.ilutionosfthisstock verepreparedfor the995 and498 mg/kg doselevels.A secondgroupofanimals(designated SecondaryDose Group)was alsoassignedtothestudyand was dosedwiththe highdoseofthetestarticleT.hese animalswere onlyused intheassayas replacementfsorany which diedintheprimarydosegroup. CHV StudyNo.: 17750-0-455 13 CORNINGHazieton Tenanimal(sfivmealeasndfivfeemalewse)rerandomlayssignteodeachdose/harvestimegroup.Vehicleand positivceontrolgroups,euthanized approximatel2y4 hoursafterdosing,were includedintheassay.The animals dosedwiththetestarticlweere euthanizedapproximately24,48 and 72 hours afterdosingforextractioonfthebone marrow. An outlineofthedosingscheme isfoundinthefollowintgable: DosingScheme forMicronucleusAssay T-6564 Treatment 498 mg/kg Number ofAnimalsAssigned PrimaryDose Groups SecondaryDose 24 Hr 48 lir 72 Hr Group ' MF MF MF MF 55 55 55 995 mg/kg 55 55 55 1990 mg/kg 55 55 55 10 10 VehicleControl.deionizedwater,10 ml/kg 55 -- -- -- PositivCeontrolC,vclophosphamide,80.0mg/kg 5 5 The animalsassignedtothesecondarydosegroupswere dosedand wereonlyusedto replaceanimalswhich diedintheprimarydosegroupatthehighdoselevel.Allextra animalsnotused asreplacementswere euthanizedatthecompletionoftheVW. A totalof 130animalswas usedinthisassay.The age oftheanimalsatthetimeof dosingwas eightweeks and one day. Volumes dosedwere 10mukg and were basedupon individuaalnimalweights. l').OBONE MARROW HARVEST, SLIDE PREPARATION AND ANALYSIS At theappropriathearvestime,theanimalswereeuthanizebdy C02/02 inhalation. followedby C02 inhalatioandpenetrationfthethorax.The adheringsofttissuaend epiphysesofbothfemorawereremoved. The marrow was flushedfrom theboneand =mferred tocentifugetubescontainin3g -5 ml bovineserum (onetubeforeach animal).Followingcentifugatiotnopelletthetissuet,hesupernatanwtas removed by aspiratioannd portionosfthepellewtere spreadon slidesand airdried.The slideswere fixedinmethanol,and staineidnMay-Grunwald solutiofnollowedby Giemsa (Schmid, 1975).The air-driesdlidewsere coverslipped. CHV StudyNo.: 17750-0455 14 CORNINGHazleton Theslidweesrecodefdoranalysainsd,scorefdormicronucalnedithepolychromatic erythrocyt(ePCE)tonormochromaticerythrocyt(eNCE) cellratioS.tandardformswere usedtorecordthesedata.One thousandPCEs peranimalwere scored.The frequencvof micronucleatedcellswas expressedaspercentmicronucleatedcellsbased on thetotal PCEs presentinthescoredopticfield.The normalfrequencyofmicronucieilnthis Crl:CD-I'O(ICRB)R straiinsabout0.0-0.4%. The frequencyofPCEs versusNCEs was determinedby scoringthenumber of PCEs and NCEs observedintheopticfieldwshilescoringthefirs1t000 erythrocytes. 14.0 EVALUATION CRITERIA 14.1 General The criterfioartheidentificatioofmnicronuclewiere thoseofSchmid (1976). Micronucleiwere darklystainedand generallryound,althoughalmond and ringshapedmicronucleoiccasionalloyccurred.Micronucleihad sharpborders and were generallbyetween 1/20and 115thesizeof thePCE. The unitof scoring was themicronucleatecdelln,otthemicronucleust;hustheoccasionaclellwith more thanone micronucleuswas countedasone micronucleatePdCE, nottwo (or more)micronucleiT.he staininpgrocedurepermittetdhedifferentiatbiyoncolor ofPCEs and NCEs (bluish-graenyd red,respectively). 14.2 Data Presentatioannd Interpretation Data aresummarizedby sexand dosegroupsforthedifferenttimepoints. Individuaalnimaldataarealsopresented.The analysisofthesedatawas performedusingan analysiosfvariance(Winer,1971)on eitheruntransformed (when variancesarehomogeneous)and ranktransformed(when variancesare heterogeneousp)roportionosf cellwsithmicronuclepieranimal.Iftheanalysis ofvariancweas significa(npt<0.05)a,Dunnett'ts-tes(tDunnett,1955;1964)was usedtodeterminewhich dosegroups,ifany,were significantdliyfferenftromthe negativecontrol.Analyseswere performedseparatelfyoreach harvesttimeand sexcombination.The criterifaordetermininga positivreesponseinvolveda statisticaslilgynificadnotse-relateidncreaseinmicronucleatePdCES, or the detectioonfa reproduciblaend statisticaslilgynificapnotsitivreesponseforat leastone doselevel.A testarticltehatinducedneithera statisticaslilgynificant dose responsenora statisticaslilgynificaanntd reproducibliencreaseatone dose levelwas considerednegative.In eithercase,thefinaldecisionwas basedon scientifjiucdgment. CHV StudyNo.: 17750-0455 is CORNINGHazieton 15.0 RESULTSAND RNTEPPRETATION Allanimalswereobservedimmediatelyafterdosingand periodicaltlhyroughouthe durationoftheassayfortoxicsymptoms and/ormortalitieAsl.lanimalsinthevehicle and positivceontrolgroupsappearednormal afterdosingand remainedhealthyuntilthe appropriathear-vesttimes.Alltestarticldeosedgroupsappearednormal inunediately afterdosing.Approximately22 hoursaftedrosing,one male (#1605)fromthesecondary dose groupwas founddead.Allotheranimalsappearednormal atthistimeand remained healthyuntiltheappropriathearvestimes. The testarticlTe-,6564,inducedno significainntcreaseisnmicronucleated polychromaticerythrocyteosverthelevelosbservedinthevehiclecontrolisneithesrex oratany oftheharvestimes.The positivceontrolC,yclophosphamide,induced significanitncreaseisnmicronucleatePdCEs inbothsexesas compared tothevehicle controlsw,ithmeans and standarderrorsof 3.86% 0.55% and 3.58% 0.79% forthe malesand females,respectivelyT.he datasummarizedby dosegroup arepresentedin Table I and individuaalnimaldataarefoundinTables2 through7. Historicaclontrol dataarepresentedinTable 8. 16.0 CONCLUSION The testmaterialT,-6564,didnotinducea significainntcreasienmicronucleinbone marrow polychromaticerythrocyteusndertheconditionosfthisassayand isconsidered negativeinthemouse micronucieusassay. CHV StudyNo.: 17750-0-455 16 CORNINGHazleton 17.0 REFERENCES Dunnet@ C.W.: A multiplecomparisonsprocedureforcomparingseveraltreatmentswith a control.J.Am. StatisAts.soc.,JQ:1096-1121,1955. Dunnett,C.W.: New tablesformultiplceomparisonswitha controlB.iometrics2,@:482491,1964. Heddle,J.A.,Hite,M.,KirkhartB,.,Larsen,K.,MacGregor,J.T.N,ewell,G.W. and Salamone,M.F.: The inductioonfmicronucleaisa measureofgenotoxicity. MutationRes.,M:61-118, 1983. Schmid,W.: The micronucieustest.MutationRes.,2J:9-15,1975. Schmid,W.: The micronucleustestforcytogenetiacnalysisC.hemical Mutagens:Principleasnd Methods forTheirDetectionV,ol.4 (A.Hollaender, ed.).Plenum,pp.31-53,1976. Winer,B.J.:StatistiPcrailncipleisnExperimentaDlesim McGraw-Hill,New York, Second Edition1,971. 18.0 DEVIATIONS FROM THE SIGNED PROTOCOL I. Inbothtrialosfthedoserangefmdingstudiesa,nimalswere observedforfour daysand notthreedavsafterdosing.Thishad no impacton studyintegrity. 2. Due toa technicaolversightm,ore than1000 erythrocytewsere analyzedfor animal#'s1576and 1628. Thishad no impacton theintegritoyfthestudy. 3. On July31,1996,forthedefinitivsetudy,thehumiditywas recordedas 75.1 Thishad no impacton theintegritoyfthestudy. CHV StudyNo.: 17750-0455 17 CORNINGHazleton i i 19.0 EX]PERIMENT DATA TABLES i 2 CHV Study No.: 17750-0-455 18 q I CORNINGHazieton TABLE I SPONSOR: 3M Corporation MICRONUCLEUS DATA SUMMARY TABLE TEST ARTICLE: T-6564 ASSAY: 17750 TREATMENT DOSE HARVEST TIME (HR) % MICRONUCLEATED PCEs MEAN OF 1000PER ANIMAL * S.E. MALES FEMALES TOTAL CONTROLS VEtflCLE POSMVE Water 24 hr 0.08* 0.06 0.08* 0.04 0.08* 0.03 CP 80.0mg&g 24 hr 3.86* 0.55* 3.58* 0.790 3.72* 0.460 RATIO PCE:NCE MEAN:L S.E. MALES FEMALES 0.53 0.08 0.61 0.05 0.73t 0.07 0.96* 0.17 TEST ARTICLE 498 mg/kg 24 hr 48 hr 72 hr 995 me&-9 24 hr 48 hr 72 hr 1990mg/kg 24 hr 48 hr 72 hr 0.20* 0.06 0.02 0.02 0.09 0.06 0.12 0.06 0.12 0.04 0.10* 0.08 0.30* 0.13 0.00* 0.00 0.08* 0.06 0.06* 0.06 0.08* 0.04 0.12* 0.07 0.18* 0.16 0.06 * 0.04 0.10* 0.06 0.09 * 0.06 0.04* 0.02 0.12 :k0.04 0.13* 0.05 0.05* 0.02 0.10* 0.04 0.15* 0.09 0.09 * 0.03 0.10* 0.05 0.19* 0.08 0.02* 0.01 0.10* 0.03 0.71 0.08 0.59* 0.05 0.52 * 0.08 0.69 .i0.12 0.63 0.03 0.45 0.08 0.69 0.07 0.60 0.06 0.49 :L 0.11 0.92 * 0.05 0.53* 0.04 1.12 * 0.43 1.03 * 0.13 0.54 * 0.06 0.95 0.21 0.75 0.07 0,56 0.07 0.78 Oll Significantglrveaterthanthecorrespondinvgehiclecontrolp,<0.05. CP - Cvclophosphamide PCE = Polvchromatiecrvthrocyte NCE = NorTnochromaticerythrocyte CHV StudyNo.: 17750-0-455 19 CORNINGHazieton TABLE2 MICRONUCLEUS TEST - INDIVIDUAL ANIMAL DATA SPONSOR: 3M Corporation TEST ARTICLE: T-6564 ASSAY NO.: 17750 TREATMENT 24 HOUR HARVEST MALE ANIMAL NUMBER # MN RATIO PCEs/ PCE:NCE 1000 PCEs VEMCLE CONTROL POSMVE CONTROL TEST ARNCLE Water CP 90.0mg/kg 498 mgtkg 995 mglkg 1990 mg/kg 1557 1 1574 0 1576 0 1585 3 1614 0 1564 46 1566 32 1569 25 1607 56 1612 34 1562 3 1570 1 issi 3 1586 3 1587 0 1568 1 1571 0 591 3 11598 2 1602 0 1558 2 1567 0 1580 8 1594 3 1611 2 0.52 0.79* 0.62 0.39 0.35 0.62 0.49 0.77 0.64 0.53 0.73 0.73 0.97 0.61 0.48 0.69 0.64 04 0I.-80 0.29 0.72 0.61 0.96 0.55 0.63 CP Cyclophosphamide PCE - Polychromaticcrarocyte # NM PCEs - MicronucleatePdCEs NCE = Normochromaticerythrocyte 1059 erythrocytesscored CHV StudyNo.: 17750-0-455 20 CORNINGHazleton TABLE3 MICRONUCLEUS TEST -INDIVIDUAL ANIMAL DATA SPONSOR: 3M Corporation TEST ARTICLE: T-6564 ASSAY NO.: 17750 TREATMENT 24 HOUR HARVEST FEMALE ANIMAL NLTMBER # MN RATIO PCEs/ PCE:NCE 1000 PCEs VEICCLE CONTROL POSITIVE CONTROL TEST ARTICLE Wamt CP 90.0mg/kg 499 mglkg 995 m&lkg 1990 mg/kg 1669 1 0.65 1671 2 0.81 1678 0 0.82 1679 1 0.89 1683 0 0.50 1641 51 0.72 1653 33 1.06 1663 56 0.57 1664 25 0.89 1667 14 1.56 1627 0 0.97 1630 0 1-00 1635 0 0.74 1644 3 0.90 1652 0 1.01 1633 0 0.78 1637 0 0.77 1660 0 0.96 1666 8 1.26 1672 1 1.39 1643 0 0.89 1650 0 0.67 1668 1 0.88 1681 3 0.53 1682 0 0.78 CP Cyclophosphamide PCE - Polychromaticrythrocvtc # MN PCF-s- MicronucleatePdCEs NCE - Nomochromatic erythrocytc CHV StudyNo.: 17750-0-455 21 CORNINGHazleton TABLE4 MICRONUCLEUS TEST - INDIVIDUAL ANIMAL DATA SPONSOR: 3M Corporation TEST ARTICLE: T-6564 ASSAY NO.: 17750 TREATMENT 48 HOUR HARVESR MALE ANIMAL NUMBER # MN RATIO PCEs/ PCE:NCE 1000 PCEs TEST ARNCLE 499 mglkg 995 mwkg 1990 1563 0 0.60 1582 0 0.75 1593 1 0.43 1603 0 0.54 1619 0 0.62 1572 1 0.67 1599 1 0.66 1596 2 0.52 1604 2 0.66 1615 0 0.62 1577 0 0.75 1579 0 0.68 1583 0 0.60 1595 0 0.41 1606 0 0.53 PCE Poivchromatiecrvthrocyte MN PCEs = Micronucleatcd PCEs NCE Norrnochromatic crythroc.vtc CHV StudyNo.: 17750-0-455 22 CORNINGHazieton TABLE5 MICRONUCLEUS TEST - INDIVIDUAL ANIMAL DATA SPONSOR: 3M Corporation TEST ARTICLE: T-6564 ASSAY NO.: 17750 TREATMENT 48 HOUR HARVEST FEMALE ANIMAL NUMBER # NfN RATIO PCEs/ PCE:NCE 1000 PCEs TEST ARTICLE 498 mgtkg "S mlag 1990 mfag 1628 2 1636 1 1639 0 1654 1 1662 0 1621 1 1649 0 1651 0 1657 0 1665 2 1626 0 632 1 11634 0 1639 1 1677 0 0.58* 0.66 0.39 0.49 0.54 0.36 0.4.4 0.57 0.71 0.59 0.40 0.64 0.49 0.77 0.51 PCE Poivchromaticerythrocyte # MN PCEs - MicronucleatePdCEs NCE = Normochromaticerythrocyte 1005 erythrocytesscored CHV StudyNo.: 17750-0455 23 CORNINGHazleton TABLE6 MICRONUCLEUS TEST - RNDIVIDUAL ANIMAL DATA SPONSOR: 3M Corpomtion TEST ARTICLE: T-6564 ASSAY NO.: 17750 TREATMENT 72 HOUR HARVEST MALE ANIMAL NUMBER # NIN RATIO PCEst PCE:NCE 1000 PCE4 TEST ARTICLE 498 mg/kg 995 mg/kg 1990 m&lkg 1561 0 0.65 565 0 0'74 11599 0 0.44 1600 3 0.34 1609 1 0.42 1555 1 0.49 1556 0 0.17 1559 0 0.59 1590 4 0.45 1597 0 0.57 1554 3 0.21 1560 1 0.78 1573 0 0.63 1613 0 0.24 1617 0 0.59 PCE Polychromatiecrythrocyte # MN PCEs = MicronucleatePdCEs NCE - Normochromaticerythrocyte CHV StudyNo.: 17750-0455 24 CORNINGHazleton TABLE7 MICRONUCLELJS TEST - INDIVIDUAL ANIMAL DATA SPONSOR: 3M Corpomtion TEST ARTICLE: T-6564 ASSAY NO.: 17750 TREATNIENT 72HOUR HARVEST FEMALE ANIMAL NUMBER # MN RATIO PCEst 1000 PCEs PCE:NCE TEST ARTICLE 498 mglkg 995 MBAs 1990 mg/kg 1619 0 0.60 1620 1 0.73 1624 0 0.45 1656 4 2.82 1680 1 0.99 1645 2 1.60 1648 3 0.79 1658 0 0.66 1674 0 0-33 1675 0 0.89 1622 1 0.67 1625 2 0.73 1629 0 0.34 1640 2 1.59 1642 1 0.56 PCE Polychromatiecrythrocyte 4 MN PCEs = MicronucieatePdCEs NCE Norrnochromaticerythrocyte CHV StudyNo.: 17750-0455 25 CORNINGHazieton TABLES MOUSE NUCRONUCLEUS HISTORICAL CONTROL DATA 7195THROUGH 12/95 POOLED VEIECLE CONTROLS MrN MAX AVG N % MICRONUCLF.ATED PCEs PER 1000 PCE MEAN Of 1000 PER ANIMAL * S.E. MALES FEMALES TOTAL 0.00 0.22 0.097:L0.007 47 0.00 014 0.081* 0.008 47 0.01 0.17 0.094* 0.005 47 RATIO PCE:NCE MEAN * S.E. MALES FEMALES 0.31 0.95 0.350* 0.021 47 014 1.03 0.587* 0.025 47 POSITIVE CONTROLS Cyclophosphwnide9,0.0mgfkg MrN MAX AVG N 2.00 5.69 3.692* 0140 19 1.50 6.36 3.170* 0145 19 2.41 5.38 3.426* 0.184 19 0.41 0.72 0.577* 0.020 19 0.40 0.79 0.598* 0.026 19 PCE = Polychromaticerythrocyte NCE = Normochromaticcrarocyte N Number ofharvests CHV StudyNo.: 17750-0-455 26